R&D News | pharmaphorum

News

Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.

News

The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.

News

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.

News

Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug.

News

Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.

News

Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.